Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Eleda Infra Services Group (“Eleda”) has entered into an agreement regarding a majority investment In Craftor Holding AB (“Craftor”).
Mandate

Eleda Infra Services Group (“Eleda”) has entered into an agreement regarding a majority investment In Craftor Holding AB (“Craftor”).

October 22, 2020 Employment and Benefits Corporate Commercial M&A Corporate Crime & Compliance EU, Competition and Regulatory Commercial Agreements IT, Telecommunications and Outsourcing Banking and Finance

Craftor’s management team will remain as shareholders in the Eleda Group and will continue their respective operative roles.

Craftor is an entrepreneur within power and force and is projecting/designing, building and providing services to power stations and distribution grids– specialised within the fields of power stations up to 400kv. As of June 2020, Craftor had a turnover of SEK 1,1 billion. Craftor operates its business similar to Eleda and will complement Eleda’s service- and maintenance business within electricity distribution.

Vinge’s team consisted of partner Christina Kokko together with associates Michaela Cronemyr, Johanna Wiberg and Hanna Risberg (M&A), Xandra Ståhlberg and Joel Kokko (Competition), Viktor Lennartsson (Banking & Finance), Isak Willborg (Agreements), Martin Boström (IT/GDPR), Ebba Svenburg (Employment), Olof Löfvenberg (Real Property & Environment), Tove Lövgren Frisk (Compliance) and Jessica Öijer (VDR Specialist).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026